Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

A Randomized Phase II Trial of Doxil With or Without Dexamethasone in Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00176293
• Other study ID #: 04-GU-52-B
• Status: Terminated
• Phase: Phase 2
• First received: September 13, 2005
• Last updated: April 20, 2015
• Start date: October 2005
• Est. completion date: February 2007

Study information

• Verified date: April 2015
• Source: University of Kentucky
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to assess disease response to Doxil in patients with hormone refractory prostate cancer with or without dexamethasone pre-treatment.

Study Design:

We will perform an open labeled, parallel, randomized phase II study using a two-stage design to determine if there is sufficient anti-tumor activity in either arm to warrant further study. Assumptions made in this study: an unacceptable overall response rate is </= 10% & we will pursue further study if the overall response rate is >/= 30%. Fifteen patients will be randomized in the first phase (to both Arm 1 and Arm 2). No further patients will be accrued if <2/15 responses are noted in a given arm. Ten additional patients will be enrolled if >/= 2/15 responses are observed. If there are >/= 5/25 responses then further studies will be pursued with that regimen. We will determine the overall incidence & severity of toxicities in both arms.

Treatment:

Arm 1: Doxil: Dose: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Arm 2: Doxil:

Dose: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Arm 1 only: Dexamethasone:

Dose: 12 mg twice a day by mouth on days 1, 2, 3, 4, 5 of each 28 day cycle.

Number of Cycles for both Arm 1 & 2: until progression or unacceptable toxicity develops.

Description:

Primary Objectives:

To assess the anti-tumor activity of Doxil by assessing response rates in patients with hormone refractory prostate cancer with or without dexamethasone pre-treatment.

Secondary Objectives:

To assess and estimate in patients with hormone refractory prostate cancer treated with Doxil with or without pre-treatment dexamethasone: 1) overall survival 2) toxicity, 3) quality of life parameters, 4) dose intensity administered in both treatment groups.

Study Design:

We will perform an open labeled, parallel, randomized phase II study using a two-stage design to determine if there is sufficient anti-tumor activity in either arm to warrant further study. Assumptions made in this study: an unacceptable overall response rate is /= 30%. The overall response rate for this study will be based on the total number of responses observed defined as: complete responses + partial responses (both by RECIST)+biochemical responses (in patients with no measurable target lesions a >/= 50% decrease in PSA for >/= 4 weeks). Fifteen patients will be randomized in the first phase (to both Arm 1 and Arm 2). No further patients will be accrued if <2/15 responses are noted in a given arm. Ten additional patients will be enrolled if >/= 2/15 responses are observed. If there are >/= 5/25 responses then further studies will be pursued with that regimen. We will determine the overall incidence and severity of toxicities in both arms.

Treatment:

Arm 1: Doxil: Dose: 50 mg/m2, IV. Frequency: day 5 of each 28 day cycle. Arm 2: Doxil: Dose:

50 mg/m2, IV. Frequency: day 5 of each 28 day cycle. Arm 1 only: Dexamethasone: Dose: 12 mg bid po. Frequency: days 1,2,3,4,5 of each 28 day cycle.

Number of Cycles for both Arm 1 and 2: until progression or unacceptable toxicity develops.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: February 2007
• Est. primary completion date: February 2007
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with metastatic hormone refractory prostate cancer as defined by resistance to both ablative therapy (with either LHRH agonists or orchiectomy) & anti-androgens.

2. Patients must have symptoms related to disease.

3. Patients must have PS 0,1,2 (ECOG).

4. Patients must have measurable disease (RECIST) or PSA > 5.

5. Patients must have adequate organ function as defined as follows: leukocytes >/= 3,000/mm3, absolute neutrophil count >/= 1,500/mm3, hemoglobin >/= 8.0g/dl, platelets >/= 100,000/mm3, serum creatinine </= 2.5 mg/dl. Bilirubin must be </= 2 fold above ULN. Liver transaminases (SGOT and/or SGPT) may be up to 2.5 x institutional ULN if alkaline phosphatase is </= ULN or alkaline phosphatase may be up to 4 x ULN if transaminases are </= ULN.

6. Patients must have a left ventricular ejection fraction (LVEF) 50% by echocardiogram

7. Patients must have failed to respond to discontinuation of anti-androgens.

8. No previous therapy with anti-androgens, corticosteroids or estrogens in the last 4 weeks.

9. Previous radiation therapy is allowed if completed at least 4 weeks prior to study entry & therapy was cumulatively administered to </= 25% of bone marrow.

10. Patients must be >18 years of age

11. Patients must have an expected survival of at least 4 months.

12. Patients must have the ability to understand & the willingness to sign a written informed consent document.

13. Patients must be willing to use adequate contraceptive method during treatment and for 3 months after completing treatment.

Exclusion Criteria:

1. Patients with previous history of cancer are excluded unless they have had curative treatment completed >/= 5 years prior to entry onto study or had 1 of the following: in situ carcinoma (any location), basal cell carcinoma, or non-metastatic squamous cell carcinoma of the skin.

2. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, uncontrolled diabetes mellitus, or psychiatric illness/social situations that would limit compliance with study requirements or the ability to provide informed consent.

3. Patients requiring any non study corticosteroids for any reason are excluded.

4. Patients who have received previous chemotherapy.

5. A history of cardiac disease with New York Heart Class II or greater, or clinical evidence of congestive heart failure.

6. Patients may not be receiving any other investigational agents or have participated in any investigational drug study within 4 weeks preceding initiation of treatment.

7. Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from major surgery.

8. Patients with a lack of physical integrity of the upper gastrointestinal tract or those who have malabsorption syndrome or inability to swallow tablets.

9. History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin HCL or the components of Doxil®

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• dexamethasone
oral dexamethasone, 12mg BID on days 1, 2, 3, 4, & 5 of each 28-day cycle
• doxorubicin
Doxorubicin 50mg/m^2 I.V. on day 5

Locations

Country	Name	City	State
United States	University of Kentucky	Lexington	Kentucky

Sponsors (2)

Lead Sponsor	Collaborator
University of Kentucky	Ortho Biotech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of subjects with CR or PR		evaluated after 2 courses then every other course	No
Secondary	Hematologic toxicity		evaluated @ baseline & 3/wk during treatment or until recovery	Yes
Secondary	Percentage of subjects with >/= Grade 3 hematopoietic & non-hematopoietic toxicities		labs evaluated @ baseline & 3/wk during treatment or until recovery; toxicity evaluated through treatment or until resolved	Yes
Secondary	Clinical non-hematologic & hematologic toxicity		continuous throughout study	Yes
Secondary	QOL		baseline then every other cycle	No
Secondary	Fraction delivered vs. intended Doxil		each dose	No
Secondary	Cytokines		evaluated days 1, 5, 8 every other cycle	Yes
Secondary	Survival		evaluated through study	No